Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies.
This open, randomized, controlled study was designed to assess the efficacy of fluconazole in comparison with oral amphotericin B in preventing clinically suspected fungal infection. A total of 178 chemotherapy-induced neutropenic episodes expected to last more than 10 days in 51 patients with haematological malignancies were randomly treated with fluconazole, 200 mg once a day, or amphotericin B, 800 mg three times a day orally. Defining the end points as (1) documented fungal infection or (2) use of empiric intravenous amphotericin B for suspected fungal infection including an episode of fever lasting more than 5 days or fever developed during the use of broad-spectrum antibiotics, no difference was observed between the two groups.
Akiyama
H
H
Haematology Division, Tokyo Metropolitan Komagome Hospital, Japan.
Mori
S
S
Tanikawa
S
S
Sakamaki
H
H
Onozawa
Y
Y
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control*; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications*; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control*; D011379:Prognosis
D000970:Antineoplastic Agents; D000666:Amphotericin B; D015725:Fluconazole